We explore the magnitude of opioid settlement funds available in Ohio; the funding mechanisms we expect ibogaine advocates to tap in support of their renewed initiative; why advocates believe Ohio makes sense as a potential champion of this work; and, the challenges ahead for such an ambitious project.
Welcome to Psychedelic Alpha.
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Plus incubation, consultancy, and advisory for this emerging field. ∎
Join over ten thousand psychedelic insiders…
For in-depth analysis and insights, consider our paid offering…
Our data and insights are cited in…
Open access data on psychedelic policy reform, patents and drug development activity.
Consultancy, advisory and incubation offerings for investors, entrepreneurs, and beyond.
Our data and insights are cited in…
INCUBATION & GROWTH
Entrepreneurs and Startups
Whether you’re at the idea-formation stage or raising early-stage funding, we’re here to help across the entire psychedelic value chain and company life-cycle.
ADVISORY & CONSULTANCY
Investors and Corporates
We help investors and corporates of all stripes understand and support the psychedelics space: from synidcates and VCs through to instituionals.
INSIGHTS & ANALYSIS
Psychedelic Insiders and the Curious
Join our newsletter to stay abreast of the rapidly emergent psychedelics industry: from clinical trials and patents through to healing centres and decriminalisation.
Our latest insights
Pα+ Psychedelic Bulletin #156: Canada’s First Published Psilocybin Trial; University of Maryland Joins Terran’s Complaint Against Compass
Canada’s First Published Psilocybin Trial Includes Patients with BDII and Personality Disorders, Employs Flexible Repeat Dosing Protocol • University of Maryland Joins Terran Biosciences’ Complaint Against Compass Pathways • and more…
Pα+: Day 2 Dispatch from ‘Advancing Psychedelic Clinical Study Design’, Hosted by the Reagan-Udall Foundation for the FDA
Our Dispatch from the second day of the Reagan-Udall Foundation for the FDA’s meeting on psychedelic clinical study design focuses on ‘set and setting’, the FDA’s regulatory authority, and ‘real world’ psychedelic use.
The Psychedelic Renaissance
After a half-century of prohibition, psychedelics are once again entering the mainstream.
Today’s so-called “psychedelic renaissance” is represented by a seemingly exponential increase in research and development activity, billions of dollars of funding, psychedelic policy reform initiatives and successes across the world, and changing public perceptions. ∎
Clinical trials involving psychedelics started, per year
Phase 3 trials of MDMA-assisted therapy have been completed, with Phase 3 study of psilocybin underway.
Invested in public and private psychedelic companies since 2020.
of psychiatrists agreed that psychedelics show promise in treating psychiatric disorders.
Barnett et al., 2023
‘Alpha’, in the investing world, refers to an excess return on investment relative to a benchmark. But we broaden the definition of alpha on both ends to include more than just economic returns on more than just economic investments.
Instead, we conceptualise alpha as the excess return on myriad investments that people may make in the present and future of psychedelics: beyond economic capital, people might invest time, energy, and effort, for example. And that excess return might not be (purely) financial, it might also be realised through a more impactful treatment paradigm for mental health, for example, where the ‘benchmark’ is the inadequate status quo.
All this to say, we’re not only for investors. In fact, most of our readers aren’t: many of them are practitioners, regulators, entrepreneurs, and so on. ∎